基于CiteSpace的肺癌免疫治疗研究的可视化分析

Visual Analysis of Research on Lung Cancer Immunotherapy by Using CiteSpace

目的了解目前肺癌免疫治疗领域的研究现状,以期为该领域深入研究和未来选题提供一定参考。方法CiteSpace可视化分析软件对2005—2021年中国知网(CNKI)收录的以“肺癌”和“免疫治疗”为关键词的400篇中文文献,以及Web of Science数据库收录的5001篇英文文献进行可视化分析。同时对Web of Science数据库收录的“Lung Cancer”和“Immunotherapy”和“Single cell sequencing”17篇英文文献进行关键词共现分析。结果“非小细胞肺癌”、“免疫抑制剂”、“PD-L1”、“树突状细胞”、“细胞因子诱导的杀伤细胞”等是目前肺癌免疫治疗研究的热点。单抗药物以纳武单抗(Nivolumab)、帕博利珠单抗(Pembrolizumab)、阿特珠单抗(Atezolizumab)和德瓦鲁单抗(Durvalumab)为热点药物。免疫治疗与化疗联合治疗、PD-L1的表达相关的研究也成为持续研究重点。肺癌免疫治疗研究在美国最多,其次为中国。结论目前我国对肺癌免疫治疗相关研究逐渐成为热点,未来需对当前研究热点进行更加深入的研究,为肺癌免疫治疗提供更为前沿的方向。

Objective To understand the current status of research on lung cancer immunotherapy to provide a reference for further investigation and future topic selection in this field.Methods CiteSpace visualization analysis software was used to analyze 400 Chinese studies in CNKI and 5001 English studies in the Web of Science database from 2005 to 2021,with“lung cancer”and“immunotherapy”as keywords.Keyword co-occurrence analysis was performed on 17 English studies of“Lung Cancer”“Immunotherapy”and“Single cell sequencing”in the Web of Science database.Results“Non-small cell lung cancer”“immunosuppressants”“PD-L1”“dendritic cells”and“cytokine-induced killer cells”are current research hotspots in lung cancer immunotherapy.Monoclonal antibody drugs including nivolumab,pembrolizumab,atezolizumab,and durvalumab are hotspot drugs.Immunotherapy combined with chemotherapy as well as PD-L1 expression have become the focus of continuous research.The majority of studies on lung cancer immunotherapy are conducted in the United States,followed by China.Conclusion Lung cancer immunotherapy has gradually become a research hot spot in China.In the future,in-depth research is needed to provide cutting-edge directions for lung cancer immunotherapy.